Andrew W Campbell1, Drew Sinatra2, Zhiwei Zhang3, Stephen T Sinatra4. 1. Medical Director of Mymycolab in Land O Lakes, Florida. 2. naturopathic doctor of integrative medicine at the CLEAR Center for Health in Mill Valley, California. 3. Department of Statistics-University of California Riverside, in Riverside California. 4. assistant clinical professor of medicine at the School of Medicine, University of Connecticut in Farmington, Connecticut.
Abstract
OBJECTIVE: The purpose of this randomized double-blind placebo controlled clinical trial was to evaluate the effects of a commercial spore-based probiotic supplement consisting of 5 different spore forming bacilli (Bacillus indicus HU36, Bacillus subtilis HU58, Bacillus coagulans SC-208, Bacillus licheniformis, and Bacillus clausii SC-109) on reducing the triglyceride levels (TG) in patients with mild to moderate hypertriglyceridemia (HT). STUDY DESIGN: A randomized, double-blind, placebo-controlled study with eighty participants with non-fasting triglyceride levels greater than 150 mg/dL. METHODS: Eighty participants with non-fasting triglyceride levels greater than 150 mg/dL were randomized to receive oral probiotic supplement consisting of two capsules containing 5 different spore forming bacilli once daily in the morning or a placebo (rice flour). Their non-fasting triglyceride levels were measured again at six weeks and at twelve weeks. RESULTS: Compared to the placebo group, participants in the probiotic supplement group had significant lowering of their triglyceride levels after 90 days. CONCLUSION: Mild to moderately elevated triglyceride levels can be lowered in patients with mild to moderate HT by a probiotic supplement consisting of five different spore forming bacilli.
OBJECTIVE: The purpose of this randomized double-blind placebo controlled clinical trial was to evaluate the effects of a commercial spore-based probiotic supplement consisting of 5 different spore forming bacilli (Bacillus indicus HU36, Bacillus subtilis HU58, Bacillus coagulans SC-208, Bacillus licheniformis, and Bacillus clausii SC-109) on reducing the triglyceride levels (TG) in patients with mild to moderate hypertriglyceridemia (HT). STUDY DESIGN: A randomized, double-blind, placebo-controlled study with eighty participants with non-fasting triglyceride levels greater than 150 mg/dL. METHODS: Eighty participants with non-fasting triglyceride levels greater than 150 mg/dL were randomized to receive oral probiotic supplement consisting of two capsules containing 5 different spore forming bacilli once daily in the morning or a placebo (rice flour). Their non-fasting triglyceride levels were measured again at six weeks and at twelve weeks. RESULTS: Compared to the placebo group, participants in the probiotic supplement group had significant lowering of their triglyceride levels after 90 days. CONCLUSION: Mild to moderately elevated triglyceride levels can be lowered in patients with mild to moderate HT by a probiotic supplement consisting of five different spore forming bacilli.
Authors: Simona Di Caro; Hong Tao; Antonino Grillo; Francesco Franceschi; Chiara Elia; Maria Assunta Zocco; Giovanni Gasbarrini; Antonia R Sepulveda; Antonio Gasbarrini Journal: Eur J Gastroenterol Hepatol Date: 2005-09 Impact factor: 2.566
Authors: Nadeem Sarwar; Manjinder S Sandhu; Sally L Ricketts; Adam S Butterworth; Emanuele Di Angelantonio; S Matthijs Boekholdt; Willem Ouwehand; Hugh Watkins; Nilesh J Samani; Danish Saleheen; Debbie Lawlor; Muredach P Reilly; Aroon D Hingorani; Philippa J Talmud; John Danesh Journal: Lancet Date: 2010-05-08 Impact factor: 79.321
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef Journal: J Clin Endocrinol Metab Date: 2012-09 Impact factor: 5.958
Authors: Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Marie Lefevre; Silvia M Racedo; Gabrielle Ripert; Béatrice Housez; Murielle Cazaubiel; Corinne Maudet; Peter Jüsten; Philippe Marteau; Maria C Urdaci Journal: Immun Ageing Date: 2015-12-03 Impact factor: 6.400